Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer

Pathology Research and Practice

Volumn 211, Issue 12, 2015, Pages 939-947

  Wang, Wu ping ^a   Yan, Xiao long ^a   Li, Wei Miao ^a   Ni, Yun feng ^a   Zhao, Jin bo ^a   Lu, Qiang ^a   Wang, Xue jiao ^a   Sun, Ying ^a   Chen, Peng ^a   Yan, Bing yang ^a   Cui, Yuanbo ^a   Zhang, Zhi Pei ^a   Li, Xiao Fei ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gankyrin; Immunohistochemistry; Lung cancer; NSCLC; Oncoprotein; Prognosis; Survival

Indexed keywords

GANKYRIN; MESSENGER RNA; ONCOPROTEIN; UNCLASSIFIED DRUG; PROTEASOME; PSMD10 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING; BIOSYNTHESIS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84954420891     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2015.09.010     Document Type: Article

References (39)

1. Reungwetwattana T., Weroha S.J., Molina J.R. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in Non-Small-Cell Lung Cancer (NSCLC). Clin. Lung Cancer 2012, 13:252-266.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 2012, 62:10-29.
3. Pfannschmidt J., Muley T., Bulzebruck H., Hoffmann H., Dienemann H. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007, 55:371-377.
4. Higashitsuji H., Itoh K., Nagao T., Dawson S., Nonoguchi K., Kido T., Mayer R.J., Arii S., Fujita J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 2000, 6:96-99.
5. Man J.H., Liang B., Gu Y.X., Zhou T., Li A.L., Li T., Jin B.F., Bai B., Zhang H.Y., Zhang W.N., Li W.H., Gong W.L., Li H.Y., Zhang X.M. Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. J. Clin. Invest. 2010, 120:2829-2841.
6. Fu X.Y., Wang H.Y., Tan L., Liu S.Q., Cao H.F., Wu M.C. p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J. Gastroenterol. 2002, 8:638-643.
7. Umemura A., Itoh Y., Itoh K., Yamaguchi K., Nakajima T., Higashitsuji H., Onoue H., Fukumoto M., Okanoue T., Fujita J. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology 2008, 47:493-502.
8. Fu J., Chen Y., Cao J., Luo T., Qian Y.W., Yang W., Ren Y.B., Su B., Cao G.W., Yang Y., Yan Y.Q., Shen F., Wu M.C., Feng G.S., Wang H.Y. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways. Hepatology 2011, 53:181-192.
9. Jing H., Zhang G., Meng L., Meng Q., Mo H., Tai Y. Gradually elevated expression of Gankyrin during human hepatocarcinogenesis and its clinicopathological significance. Sci. Rep. 2014, 4:5503.
10. Ortiz C.M., Ito T., Tanaka E., Tsunoda S., Nagayama S., Sakai Y., Higashitsuji H., Fujita J., Shimada Y. Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance. Int. J. Cancer 2008, 122:325-332.
11. Bai Z., Tai Y., Li W., Zhen C., Gu W., Jian Z., Wang Q., Lin J.E., Zhao Q., Gong W., Liang B., Wang C., Zhou T. Gankyrin activates IL-8 to promote hepatic metastasis of colorectal cancer. Cancer Res. 2013, 73:4548-4558.
12. Meng Y., He L., Guo X., Tang S., Zhao X., Du R., Jin J., Bi Q., Li H., Nie Y., Liu J., Fan D. Gankyrin promotes the proliferation of human pancreatic cancer. Cancer Lett. 2010, 297:9-17.
13. Kim Y.H., Kim J.H., Choi Y.W., Lim S.K., Yim H., Kang S.Y., Chung Y.S., Lee G.Y., Park T.J. Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression. Exp. Mol. Pathol. 2013, 94:360-365.
14. Zheng T., Hong X., Wang J., Pei T., Liang Y., Yin D., Song R., Song X., Lu Z., Qi S., Liu J., Sun B., Xie C., Pan S., Li Y., Luo X., Li S., Fang X., Bhatta N., Jiang H., Liu L. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology 2014, 59:935-946.
15. Zhang J., Yang Y., Zhang Z., He Y., Liu Z., Yu Y., Wu S., Cai B., Feng Y. Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway. Cancer Lett. 2013, 339:279-287.
16. Liu Y., Zhang J., Qian W., Dong Y., Yang Y., Liu Z., Feng Y., Ma D., Zhang Z., Wu S. Gankyrin is frequently overexpressed in cervical high grade disease and is associated with cervical carcinogenesis and metastasis. PLoS One 2014, 9:pe95043.
17. Li J., Knobloch T.J., Kresty L.A., Zhang Z., Lang J.C., Schuller D.E., Weghorst C.M. Gankyrin, a biomarker for epithelial carcinogenesis, is overexpressed in human oral cancer. Anticancer Res. 2011, 31:2683-2692.
18. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., Postmus P.E., Rusch V., Sobin L. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2007, 2:706-714.
19. Travis W.D., Brambilla E., Burke A.P., Alexander M., Nicholsonm A.G. Tumours of the Lung, Pleura, Thymus and Heart, World Health Organization Classification of Tumors 2015, IARC Press, Lyon, France.
20. Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J. Thorac. Oncol. 2011, 6:1496-1504.
21. Warth A., Muley T., Meister M., Stenzinger A., Thomas M., Schirmacher P., Schnabel P.A., Budczies J., Hoffmann H., Weichert W. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J. Clin. Oncol. 2012, 30:1438-1446.
22. Saeki Y., Toh-E A., Kudo T., Kawamura H., Tanaka K. Multiple proteasome-interacting proteins assist the assembly of the yeast 19S regulatory particle. Cell 2009, 137:900-913.
23. Li J., Mahajan A., Tsai M.D. Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry 2006, 45:15168-15178.
24. Dawson S., Apcher S., Mee M., Higashitsuji H., Baker R., Uhle S., Dubiel W., Fujita J., Mayer R.J. Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome. J. Biol. Chem. 2002, 277:10893-10902.
25. Higashitsuji H., Higashitsuji H., Itoh K., Sakurai T., Nagao T., Sumitomo Y., Masuda T., Dawson S., Shimada Y., Mayer R.J.J. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005, 8:75-87.
26. Tang S., Yang G., Meng Y., Du R., Li X., Fan R., Zhao L., Bi Q., Jin J., Gao L., Zhang L., Li H., Fan M., Wang Y., Wu K., Liu J., Fan D. Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol. Ther. 2010, 9:88-95.
27. Zhen C., Chen L., Zhao Q., Liang B., Gu Y.X., Bai Z.F., Wang K., Xu X., Han Q.Y., Fang D.F., Wang S.X., Zhou T., Xia Q., Gong W.L., Wang N., Li H.Y., Jin B.F., Man J.H. Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity. Oncogene 2013, 32:3452-3460.
28. Rinaldi A.S., Freund G., Desplancq D., Sibler A.P., Baltzinger M., Rochel N., Mely Y., Didier P., Weiss E. The use of fluorescent intrabodies to detect endogenous gankyrin in living cancer cells. Exp. Cell Res. 2013, 319:838-849.
29. Luo X., Chen L., Dai J., Gao Y., Wang H., Wang N., Zhao Y., Liu F., Sang Z., Wang J., Li W., He K., Jin B., Man J., Zhang W., Xia Q. Gankyrin gene deletion followed by proteomic analysis: insight into the roles of Gankyrin in tumorigenesis and metastasis. BMC Med. Genomics 2012, 5:36.
30. Dong L.W., Yang G.Z., Pan Y.F., Chen Y., Tan Y.X., Dai R.Y., Ren Y.B., Fu J., Wang H.Y. The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling. Cell Res. 2011, 21:1248-1261.
31. Song X., Wang J., Zheng T., Song R., Liang Y. LBH589 inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol. Cancer 2013, 12(1):114.
32. Song X., Wang J., Zheng T., Song R., Liang Y., Bhatta N., Yin D., Pan S., Liu J., Jiang H., Liu L. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol. Cancer 2013, 12:114.
33. Gao L., Xie H., Dong L., Zou J., Fu J., Gao X., Ou L., Xiang S., Song H. Gankyrin is essential for hypoxia enhanced metastatic potential in breast cancer cells. Mol. Med. Rep. 2014, 9:1032-1036.
34. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
35. Tischler V., Pfeifer M., Hausladen S., Schirmer U., Bonde A.K., Kristiansen G., Sos M.L., Weder W., Moch H., Altevogt P., Soltermann A. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol. Cancer 2011, 10:127.
36. Feng J., Zhang X., Zhu H., Wang X., Ni S. FoxQ1 overexpression influences poor prognosis in non-small cell lung cancer, associates with thephenomenon of EMT. PLoS One 2012, 7:e39937.
37. Bae G.Y., Choi S.J., Lee J.S., Jo J., Lee J., Kim J., Cha H.J. Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget 2013, 4:2512-2522.
38. Sun M., Liu X.H., Wang K.M., Nie F.Q., Kong R., Yang J.S., Xia R., Xu T.P., Jin F.Y., Liu Z.J., Chen J.F., Zhang E.B., De W., Wang Z.X. Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol. Cancer 2014, 21:13-68.
39. Chen L., Muñoz-Antonia T., Cress W.D. Trim28 contributes to EMT via regulation of E-cadherin and N-cadherin in lung cancer cell lines. PLoS One 2014, 9:e101040.